Arcturus Therapeutics Holdings (ARCT) Interest Expenses (2018 - 2026)

Arcturus Therapeutics Holdings' Interest Expenses history runs 9 years deep, the most recent figure standing at $27.7 million for Q1 2026.

• Quarterly Interest Expenses fell 15.0% year-over-year to $27.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.7 million (down 15.0% YoY) and the FY2025 annual result came in at $143.5 million, up 3.97% from the prior year.
• Interest Expenses was $27.7 million for Q1 2026 at Arcturus Therapeutics Holdings, down from $143.5 million in the prior quarter.
• Across five years, Interest Expenses topped out at $143.5 million in Q4 2025 and bottomed at $25000.0 in Q4 2023.
• A 5-year average of $35.4 million and a median of $30.3 million in 2025 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses plunged 89.04% — and 2024, when it jumped 552076.0%.
• Arcturus Therapeutics Holdings' Interest Expenses stood at $228000.0 in 2022, then plunged by 89.04% to $25000.0 in 2023, then soared by 552076.0% to $138.0 million in 2024, then advanced by 3.97% to $143.5 million in 2025, then sank by 80.71% to $27.7 million in 2026.
• Business Quant data shows ARCT's Interest Expenses at $27.7 million in Q1 2026, $143.5 million in Q4 2025, and $30.3 million in Q3 2025.